A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in IMRT for Head and Neck Cancer

Sponsor
Hebei Provincial Hospital of Traditional Chinese Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05539144
Collaborator
(none)
20
1
1
14
1.4

Study Details

Study Description

Brief Summary

The investigators tries a new method to delineating the oral cavity, oropharynx, larynx and hypopharynx, and use the head-and-neck region to test whether the method can to create a good IMRT plan, and alleviate the oral radiation injury, reduce the incidence of adverse reactions.

Condition or Disease Intervention/Treatment Phase
  • Radiation: Delineation for organs at risks (OARs) in IMRT plan
N/A

Detailed Description

Purpose: To assess the dosimetric effect of new delineation approach for oral cavity, oropharynx, larynx and hypopharynx in intensity-modulated radiotherapy(IMRT) treatment planning for head and neck cancer.

Methods: Twenty head and neck cancer patients were treated by IMRT. Target volumes and several organs at risk were delineated with Corvus6.3 treatment planning system. An investigative IMRT plan was generated based on a standard treatment planning protocol, but used a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx. Plans were exported to treatment planning system for quantitative analysis of dose volume parameters. Variables assessed included: maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (EUD), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (OARs) doses, and dose homogeneity inside the target volumes.

.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A New Delineation Approach for Oral Cavity, Oropharynx, Larynx and Hypopharynx in Intensity-modulated Radiation Treatment for Head and Neck Cancer
Anticipated Study Start Date :
Oct 11, 2022
Anticipated Primary Completion Date :
Oct 11, 2023
Anticipated Study Completion Date :
Dec 11, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: new delineation approach for oral cavity, oropharynx, larynx and hypopharynx.

An investigative IMRT plan was generated based on a standard treatment planning protocol, but used a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx.

Radiation: Delineation for organs at risks (OARs) in IMRT plan
An adaptive contouring brush within the planning software was used to create a new structure: the air cavity within oral cavity, oropharynx, larynx and hypopharynx, and the new structure was expanded and shrunk uniformly 2 mm to create the oral cavity, oropharynx, larynx and hypopharynx

Outcome Measures

Primary Outcome Measures

  1. Dose distribution [through study completion, an average of 1 year]

    maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (EUD), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (OARs) doses, and dose homogeneity inside the target volumes.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with previously untreated of the head and neck cancer who received definitive IMRT at our institution
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Radiotherapy, Hebei Province Hospital of Chinese Medicine Shijiazhuang Hebei China 050011

Sponsors and Collaborators

  • Hebei Provincial Hospital of Traditional Chinese Medicine

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xueqi Wang, Principal Investigator, Hebei Provincial Hospital of Traditional Chinese Medicine
ClinicalTrials.gov Identifier:
NCT05539144
Other Study ID Numbers:
  • HebeiProvincial
First Posted:
Sep 14, 2022
Last Update Posted:
Sep 14, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2022